Melanoma, Cutaneous Malignant: all 135 studies
Page 1 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- APA (Adapted Physical Activity) for Patients With Advanced MelanomaRecruitingNCT07031830
- Clinical Genetics Branch Eligibility Screening SurveyNot yet recruitingNCT07005297
- Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II TrialRecruitingNCT06965231Phase 2
- Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitisRecruitingNCT06899789
- EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control TrialRecruitingNCT06767332Not applicable
- The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.RecruitingNCT06765850
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingNCT06743126Phase 3
- An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.Not yet recruitingNCT06661577
- MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)RecruitingNCT06602648
- Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma PatientsEnrolling by invitationNCT06388252Not applicable
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsRecruitingNCT06090266Phase 1/2
- Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous MelanomaRecruitingNCT05907512Phase 2
- The MELAcare Study: A New Method for Surveillance of Melanoma PatientsRecruitingNCT05253872Not applicable
- Irradiation of Melanoma in a PulseRecruitingNCT04986696Not applicable
- IFx-Hu2.0 Expanded Access ProgramAvailableNCT04853602
- Registry of Subjects at Risk of Pancreatic CancerRecruitingNCT04095195
- Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaRecruitingNCT03860883Not applicable
- Pancreas Registry and High Risk RegistryRecruitingNCT02775461
- Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
- Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
- pDNA Intralesional Cancer Vaccine for Cutaneous MelanomaCompletedNCT03655756Early Phase 1Results posted
- Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous MetastasesCompletedNCT03628417Not applicableResults posted
- Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaCompletedNCT03396952Phase 2Results posted
- Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaTerminatedNCT03325101Phase 1/2Results posted
- Strategies to Promote Skin HealthCompletedNCT03237013Not applicableResults posted
- Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
- Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerCompletedNCT03154190Not applicableResults posted
- Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
- Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTerminatedNCT02748564Phase 2Results posted
- Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
- Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
- Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
- Survivorship Promotion In Reducing IGF-1 TrialCompletedNCT02431676Phase 2Results posted
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
- PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous MelanomaTerminatedNCT02288897Phase 3Results posted
- A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
- Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
- Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV MelanomaCompletedNCT01961115Phase 2Results posted
- Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)CompletedNCT01928940Phase 2Results posted
- Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
- Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by SurgeryCompletedNCT01886235Not applicableResults posted
- Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic MelanomaCompletedNCT01807182Phase 2Results posted
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaCompletedNCT01763164Phase 3Results posted
- Vitamin D Supplementation in Cutaneous Malignant Melanoma OutcomeCompletedNCT01748448Phase 3Results posted
- Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaCompletedNCT01740557Phase 1/2Results posted
- Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedNCT01693068Phase 2Results posted
- Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
- Recombinant Interferon Alfa-2b in Treating Patients With MelanomaCompletedNCT01460875Not applicableResults posted
- Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
- Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous MelanomaCompletedNCT01213472Phase 1Results posted
- Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous MelanomaCompletedNCT00896480Phase 2Results posted
- MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00866177Phase 2Results posted
- MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous MelanomaTerminatedNCT00706238Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
- Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
- Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous MelanomaTerminatedNCT00145158Phase 1/2Results posted
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
- Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
- Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based StudyCompletedNCT06705608
- Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma PatientsCompletedNCT06152367Phase 1/2
- A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnNCT05572463Phase 1/2
- Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2
- Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 1
- Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
- The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma PatientsCompletedNCT05102773
- Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
- Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic ManagementCompletedNCT04789421Not applicable
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesCompletedNCT04752267Early Phase 1
- Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.Status unknownNCT04625491
- Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in CancerActive, not recruitingNCT04620603Phase 1
- Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
- Interpolated Flap StudyCompletedNCT04164550
- Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility StudyCompletedNCT04074460Phase 4
- Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
- A Study To See Why Patients Agree To or Decline To Have Treatment After SurgeryCompletedNCT03843593
- MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedNCT03761017Phase 1
- Intralesional Sclerosant for in Transit and Cutaneous Melanoma MetastasesWithdrawnNCT03754140Phase 2
- CBL0137 in Treating Patients With Advanced Extremity Melanoma or SarcomaTerminatedNCT03727789Phase 1
- A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk GroupsCompletedNCT03693378
- Advanced Melanoma in Russian ExperienceCompletedNCT03663647
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 1
- Evaluation of Oncoxin-Viusid® in Cutaneous MelanomaCompletedNCT03541148Phase 2
- Impact of Dietary Intervention on Tumor Immunity: the DigesT TrialStatus unknownNCT03454282Not applicable
- Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
- Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their PartnersCompletedNCT03112668Not applicable
- Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous MelanomaTerminatedNCT02968680Phase 1
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2
- Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node BiopsyCompletedNCT02857374Not applicable
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
- Impact of Obstructive SAS on Metastatic Potential of Cutaneous MelanomaWithdrawnNCT02699918Early Phase 1
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
- Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1
- Improving Sun-Protective Behaviors and Skin Self-Examinations Among African AmericansCompletedNCT02417948Not applicable
- Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous MelanomaNo longer availableNCT02416232